<DOC>
	<DOCNO>NCT00004145</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill cancer cell . Sometimes transplanted cell reject body 's normal tissue . Antithymocyte globulin may prevent happen . PURPOSE : Phase II trial study effectiveness chemotherapy plus biological therapy follow peripheral stem cell transplantation treat patient hematologic cancer .</brief_summary>
	<brief_title>Chemotherapy Plus Biological Therapy Followed By Peripheral Stem Cell Transplantation Treating Patients With Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine effect nonmyeloablative chemotherapy follow allogeneic peripheral blood stem cell transplantation hematopoietic recovery patient hematologic malignancy . II . Determine toxicity regimen patient . III . Determine frequency mix hematopoietic chimerism patient therapy . IV . Determine efficacy toxicity donor leukocyte infusion relapse patient . V. Determine response rate survival patient therapy . VI . Determine immune reconstitution patient undergoing therapy . OUTLINE : Patients receive fludarabine IV 30 minute day -9 -5 , cyclophosphamide IV 1 hour day -5 , antithymocyte globulin IV 10 hour day -5 -2 . Allogeneic peripheral blood stem cell infuse day 0 . Patients achieve complete remission ( CR ) relapse patient achieve less CR day 60 receive donor leukocyte infusion ( DLI ) 30 minute . DLI repeat necessary persistent disease . Patients follow 1 , 3 , 6 month , 1 2 year . PROJECTED ACCRUAL : A total 40 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove hematologic malignancy standard curative therapy , include , limited : Low grade nonHodgkin 's lymphoma ( NHL ) Mantle cell lymphoma Chronic lymphocytic leukemia ( stage IIIV ) Myelodysplastic syndrome , include : Refractory anemia ( RA ) ring sideroblast RA excess blast ( RAEB ) RAEB transformation Chronic myelomonocytic leukemia Multiple myeloma OR Histologically proven hematologic malignancy fail 1 prior therapy OR high risk relapse , include , limited : Intermediate grade NHL High grade NHL Hodgkin 's disease Acute lymphoblastic lymphoma Acute myelogenous leukemia OR Histologically proven chronic myelogenous leukemia chronic accelerate phase , follow risk factor preclude eligibility standard allogeneic peripheral blood stem cell transplantation : Older age Poor performance status Healthy , partially relate HLA 5/6 6/6 serologic match donor available A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age : 18 60 physiologic 70 Performance status : Karnofsky 02 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin le 2.0 mg/dL SGOT SGPT less 2 time normal No active hepatitis Renal : Creatinine le 2.0 mg/dL OR Creatinine clearance great 50 mL/min Cardiovascular : Ejection fraction great 45 % OR Cardiac clearance Pulmonary : DLCO least 50 % predict Other : No active infection HIV1 , HIV2 , HTLV1 negative Not pregnant nurse PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>refractory anemia</keyword>
	<keyword>refractory anemia ring sideroblast</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>